Cationic lipids for use in lipid nanoparticles
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Compounds are provided having the following structure: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.
Core Innovation
The invention is directed to a compound having a structure of Formula (I), or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. The Formula (I) structure specifies substituent groups including G1 and G2 as independently C1-C6 alkylene, L1 and L2 as independently —O(C=O)O— or —(C=O)O—O—, and multiple R-group positions defined by alkyl or unsaturation rules. Additional structural definition includes R5 and R6 as each independently H or methyl, R7 as —O(C=O)R10, —(C=O)OR10, —NR9(C=O)R10, or —(C=O)NR9R10, and R8 as OH, —N(R11)(C=O)R12, —(C=O)NR11R12, —NR11R12, —(C=O)OR12, or —O(C=O)R12.
The Formula (I) also defines R9 as H or C1-C15 alkyl, R10 as C1-C15 alkyl, R11 as H or C1-C6 alkyl, and R12 as C1-C6 alkyl. The structure includes X as —(C=O)— or a direct bond and integer parameters a, b, c and d as each independently an integer from 1 to 24, with each methyl, alkyl and alkylene optionally substituted. Example compounds are illustrated for structure (I) as multiple drawn chemical structures, showing a multi-chain scaffold with tertiary/secondary amine segments and ester/carboxylate motifs.
The disclosed subject matter further provides lipid nanoparticles comprising the structure (I) compound, with optional neutral lipids and other lipid components. In particular, the lipid nanoparticles include cholesterol and pegylated lipids such as PEG-DAG, PEG-PE, PEG-S-DAG, PEG-cer, and related PEG carbamate forms, with compound-to-lipid component molar ratio ranges given for neutral lipid, cholesterol, and pegylated lipid. Therapeutic agent compositions are described as potentially including nucleic acids, including antisense or messenger RNA, and these nucleic acids may be delivered in the lipid nanoparticles.
Claims Coverage
The provided claim coverage identifies one independent claim directed to a compound of Formula (I), and a formulation embodiment directed to a lipid nanoparticle including the compound and an mRNA encoding a protein.
Compound of formula (I) with defined substituent pattern
A compound having a structure of Formula (I) (or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof) wherein G1 and G2 are each independently C1-C6 alkylene; L1 and L2 are each independently —O(C=O)O— or —(C=O)O—O—; multiple R-group positions are each independently selected based on H/alkyl options and double-bond formation rules; R5 and R6 are each independently H or methyl; R7 and R8 are defined by specified heteroatom-containing carbonyl/amide-like forms; R9 is H or C1-C15 alkyl; R10 is C1-C15 alkyl; R11 is H or C1-C6 alkyl; R12 is C1-C6 alkyl; X is —(C=O)— or a direct bond; and a, b, c and d are each independently an integer from 1 to 24 with optional substitution of methyl, alkyl and alkylene.
Lipid nanoparticle comprising the compound of formula (I) and mRNA
A lipid nanoparticle that includes the compound of Formula (I) and an mRNA encoding a protein.
The core inventive subject matter is the defined Formula (I) compound, including its salt, tautomer, and stereoisomer variants, and a formulation embodiment in which that compound is included in a lipid nanoparticle carrying mRNA encoding a protein.
Stated Advantages
Serum protection.
Improved intracellular delivery.
Increased activity.
Improved in vivo tolerability with an increased therapeutic index.
Documented Applications
Treatment applications using lipid nanoparticles with nucleic acid therapeutic payloads, including mRNA, antisense oligonucleotide, siRNA/miRNA, miRNA inhibitors, plasmid DNA, and antisense RNA.
Vaccination applications in a viral pathogen antigen context using lipid nanoparticle delivery.
Administration of LNP compositions to patients.
Luciferase mRNA evaluation and in vivo liver luciferase expression context.
Interested in licensing this patent?